Get the Stockscreener App
5.96
0.51%
0.03
Pre-market:
5.87
-0.09
-1.51%
Vir Biotechnology Inc stock is traded at $5.96, with a volume of 913.13K.
It is up +0.51% in the last 24 hours and up +4.38% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$5.93
Open:
$5.87
24h Volume:
913.13K
Relative Volume:
0.65
Market Cap:
$827.94M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.5204
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
-0.33%
1M Performance:
+4.38%
6M Performance:
-2.61%
1Y Performance:
-20.43%
1-Day Range:
$5.76
$5.98
1-Week Range:
$5.76
$6.555
52-Week Range:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.96 | 823.77M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
How Vir Biotechnology Inc. stock reacts to oil pricesGap Down & High Yield Equity Trading Tips - newser.com
Will Vir Biotechnology Inc. stock deliver consistent dividends2025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com
Why Vir Biotechnology Inc. stock remains on watchlistsWeekly Risk Summary & Reliable Volume Spike Trade Alerts - newser.com
Best data tools to analyze Vir Biotechnology Inc. stockMarket Sentiment Report & AI Forecast for Swing Trade Picks - newser.com
Risk adjusted return profile for Vir Biotechnology Inc. analyzedQuarterly Portfolio Report & Safe Capital Growth Tips - newser.com
Vir Biotechnology Hits Day Low of $5.87 Amid Price Pressure - Markets Mojo
Pattern recognition hints at Vir Biotechnology Inc. upside2025 Earnings Impact & Short-Term Trading Opportunity Alerts - newser.com
Top chart patterns to watch in Vir Biotechnology Inc.July 2025 PostEarnings & Reliable Price Breakout Alerts - newser.com
Why Vir Biotechnology Inc. stock is favored by top institutions - newser.com
Vir Biotechnology Inc. stock trendline breakdownJuly 2025 Macro Moves & Real-Time Buy Zone Alerts - newser.com
What analysts say about Vir Biotechnology Inc stockHigh Beta Stocks & Market Analysis Tools You Can Trust - earlytimes.in
Is Vir Biotechnology Inc. forming a reversal patternAnalyst Upgrade & Free Real-Time Market Sentiment Alerts - newser.com
Is now a turning point for Vir Biotechnology Inc.Stock Surge & Real-Time Market Sentiment Alerts - newser.com
Can technical indicators confirm Vir Biotechnology Inc.’s reversal2025 Volatility Report & Proven Capital Preservation Tips - newser.com
How to escape a deep drawdown in Vir Biotechnology Inc.July 2025 Fed Impact & Expert Approved Momentum Trade Ideas - newser.com
Tools to monitor Vir Biotechnology Inc. recovery probabilityTrend Reversal & Expert Verified Stock Movement Alerts - newser.com
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 24,453 Shares - MarketBeat
Vir Biotechnology’s Phase 1 Study on VIR-5525: A Potential Game-Changer in Cancer Treatment? - MSN
How Vir Biotechnology Inc. stock reacts to inflationary pressuresWeekly Stock Report & Fast Gaining Stock Reports - newser.com
What the charts say about Vir Biotechnology Inc. todayJuly 2025 Update & Fast Exit Strategy with Risk Control - newser.com
Vir Biotechnology Form 4: 10b5-1 sales; 14,573,983 shares remain - Stock Titan
Vir Biotechnology’s Hepatic Impairment Study: A Potential Game Changer? - MSN
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 46,696 Shares - MarketBeat
Endurance (Cayman) Ltd Svf Sells 66,403 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Vir Biotechnology, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
VIR insider filing shows October sales under 10b5‑1 plan - Stock Titan
With 59% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backing - Yahoo Finance
How buybacks impact Vir Biotechnology Inc. stock value2025 Geopolitical Influence & Weekly High Return Stock Opportunities - fcp.pa.gov.br
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vir Biotechnology Inc Stock (VIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 29 '25 |
Sale |
6.49 |
100 |
649 |
14,573,983 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 27 '25 |
Sale |
6.05 |
66,403 |
401,585 |
14,598,536 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 24 '25 |
Sale |
5.96 |
46,696 |
278,285 |
14,664,939 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 23 '25 |
Sale |
5.99 |
154,383 |
924,723 |
14,711,635 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 22 '25 |
Sale |
6.15 |
144,266 |
887,654 |
14,866,018 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 20 '25 |
Sale |
6.20 |
220,535 |
1,367,273 |
15,119,959 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 21 '25 |
Sale |
6.30 |
109,675 |
690,974 |
15,010,284 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):